Identification of multiple sources of charge heterogeneity in a recombinant antibody.

Seven forms of a therapeutic recombinant antibody that binds to the her2/neu gene product were resolved by cation-exchange chromatography. Structural differences were assigned by peptide mapping and HIC after papain digestion. Deamidation of light chain asparagine 30 to aspartate in one or both light chains is responsible for two acidic forms. A low potency form is due to isomerization of heavy chain aspartate 102; the Asp102 succinimide is also present in a basic peak fraction. Forms with both Asn30 deamidation and Asp102 isomerization modifications were isolated. Deamidation of heavy chain Asn55 to isoaspartate was also detected. Isoelectric focusing in a polyacrylamide gel was used to verify the assignments. All modifications were found in complementarity determining regions.

[1]  R. Jefferis,et al.  Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G. , 1987, Biochemistry.

[2]  Y. J. Wang,et al.  Formulation, Characterization, and Stability of Protein Drugs: Case Histories , 2002, Pharmaceutical Biotechnology.

[3]  Reed J. Harris,et al.  Identification of succinimide sites in proteins by N‐terminal sequence analysis after alkaline hydroxylamine cleavage , 1994, Protein science : a publication of the Protein Society.

[4]  B. Violand,et al.  Isolation and characterization of porcine somatotropin containing a succinimide residue in place of aspartate129 , 1992, Protein science : a publication of the Protein Society.

[5]  R. Bischoff,et al.  Sequence-specific deamidation: isolation and biochemical characterization of succinimide intermediates of recombinant hirudin. , 1993, Biochemistry.

[6]  M. Sliwkowski,et al.  Assessing Genetic Heterogeneity in Production Cell Lines: Detection by Peptide Mapping of a Low Level Tyr to Gln Sequence Variant in a Recombinant Antibody , 1993, Nature Biotechnology.

[7]  H. Wright.  Sequence and structure determinants of the nonenzymatic deamidation of asparagine and glutamine residues in proteins. , 1991, Protein engineering.

[8]  L. Presta,et al.  X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.

[9]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[10]  S. Clarke,et al.  Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. , 1987, The Journal of biological chemistry.

[11]  S. Moore,et al.  On the sequence of residues 11 to 18 in bovine pancreatic ribonuclease. , 1962, The Journal of biological chemistry.

[12]  D. Marshak,et al.  TECHNIQUES IN PROTEIN CHEMISTRY VII , 1996 .

[13]  W. Nashabeh,et al.  Capillary electrophoresis sodium dodecyl sulfate nongel sieving analysis of a therapeutic recombinant monoclonal antibody: a biotechnology perspective. , 1999, Analytical chemistry.

[14]  A. Alexander,et al.  Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry. , 1995, Analytical chemistry.

[15]  M. Mulkerrin,et al.  Rapid analytical tryptic mapping of a recombinant chimeric monoclonal antibody and method validation challenges. , 1997, Journal of pharmaceutical and biomedical analysis.

[16]  Y. J. Wang,et al.  Stability and Characterization of Protein and Peptide Drugs , 1993, Pharmaceutical Biotechnology.

[17]  J. Stults,et al.  Isolation and characterization of a succinimide variant of methionyl human growth hormone. , 1991, The Journal of biological chemistry.

[18]  A. Kossiakoff,et al.  Tertiary structure is a principal determinant to protein deamidation. , 1988, Science.

[19]  M J Keen,et al.  Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. , 1995, Glycobiology.

[20]  W. Hancock,et al.  Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS, and MS/MS. , 1994, Analytical chemistry.

[21]  T. Ueda,et al.  Isolation and characterization of 101-succinimide lysozyme that possesses the cyclic imide at Asp101-Gly102. , 1994, Biochemistry.

[22]  S. Carr,et al.  An integrated strategy for structural characterization of the protein and carbohydrate components of monoclonal antibodies: application to anti-respiratory syncytial virus MAb. , 1995, Analytical chemistry.

[23]  M. Mulkerrin,et al.  Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion. , 1997, Journal of pharmaceutical and biomedical analysis.

[24]  J. Briggs,et al.  A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. , 1998, Glycobiology.

[25]  L. Presta,et al.  Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. , 1992, Biochemistry.

[26]  L. Presta,et al.  Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. , 1996, Biochemistry.